EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN'S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY

Marc Ferrante  1     Tadakazu Hisamatsu  2     Xiaomei Liao  3     Yinuo Pang  3     Valerie Pivorunas  3    
1 University Hospitals Leuven, Leuven, Belgium
2 Kyorin University School of Medicine, Tokyo, Japan
3 AbbVie, North Chicago, United States

Topic
IBD

Session
Late-breaking Abstracts III: Clinical trials in IBD

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)

Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing